0001193125-26-209116
SEC filingSight Sciences delivered revenue growth and narrowed operating and net losses in Q1 FY2026, reflecting continued commercial execution and cost discipline — though the company remains in a pre-profitability investment phase with negative operating cash flow.
Revenue increased 12.5% year-over-year to $19.7 million, driven by continued adoption of our interventional platforms. As noted in management commentary, Interventional Dry Eye customers respond to clinical outcomes and procedural efficiency, while Interventional Glaucoma customers place orders based on expected procedure volume — suggesting demand remains anchored in real-world utility rather than short-term promotional activity.